Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US Accessibility StatementSkip NavigationNew US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6SHELTON, Conn., March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development ...